Oruka Therapeutics
ORKA
81 hedge funds and large institutions have $386M invested in Oruka Therapeutics in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 15 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
18% more capital invested
Capital invested by funds: $326M → $386M (+$59.9M)
14% more funds holding
Funds holding: 71 → 81 (+10)
7.08% more ownership
Funds ownership: 84.87% → 91.96% (+7.1%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.9M |
| 2 |
Mercer Global Advisors
Denver,
Colorado
|
+$8.88M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$4.94M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.7M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$3.97M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$3.54M |
| 3 |
Morgan Stanley
New York
|
-$3.33M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.29M |
| 5 |
Goldman Sachs
New York
|
-$1.79M |
ORKA Hedge Fund Activity: Q2 2025 in Review
81 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2025, worth a combined $386M — up 18% from $326M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ORKA positions and 15 closed out — a net gain of 10 holders — while 27 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was Redmile Group, exiting entirely with an estimated $3.97M sold.
- 81 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2025, up from 71 in Q1 2025.
- Funds reported $386M of Oruka Therapeutics stock for Q2 2025, up 18% quarter-over-quarter.
- 25 funds opened new Oruka Therapeutics positions in Q2 2025 and 15 closed out, a net change of +10 holders.
- The largest Oruka Therapeutics buyer in Q2 2025 was BlackRock, an estimated $12.9M added.
- The largest Oruka Therapeutics seller in Q2 2025 was Redmile Group, an estimated $3.97M sold.
Based on aggregated 13F filings for Q2 2025.